ClinicalTrials.Veeva
Menu

Find clinical trials for Colon Cancer in Washington, DC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Colorectal Cancer
Colonic Cancer
Cancer
Neoplasm Metastasis
Adenocarcinoma
Lung Cancer
Non-Small-Cell Lung Carcinoma

Colon Cancer trials near Washington, DC, USA:

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer (AZUR-2)

(SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon...

Enrolling
Colonic Neoplasms
Neoplasms, Colon
Drug: FOLFOX
Biological: Dostarlimab

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Washington, District of Columbia, United States and 212 other locations

and anti-PD-1 antibody nivolumab in relapsed/refractory solid tumors with expansions in mismatch-repair proficient (MSS) colorectal cancer....

Active, not recruiting
Colon Cancer
Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor Along With Microsatellite Stable (MSS) Colon Cancer
Drug: Copanlisib
Drug: Nivolumab

Phase 1, Phase 2

Johns Hopkins Medicine
Johns Hopkins Medicine

Baltimore, Maryland, United States

or metastatic mismatch repair-proficient (MMR-p) colorectal cancer (mCRC) or unresectable or metastatic MMR-p pancreatic ductal adenocarcino...

Begins enrollment in 1 month
Pancreatic Cancer
Colorectal Cancer
Drug: KRAS Vaccine with Poly-ICLC adjuvant
Drug: Botensilimab

Phase 2

Johns Hopkins Medicine
Johns Hopkins Medicine

Baltimore, Maryland, United States

This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with isocitr...

Active, not recruiting
Glioma
Chondrosarcoma
Drug: LY3410738
Drug: Gemcitabine

Phase 1

Lilly
Lilly

Baltimore, Maryland, United States and 32 other locations

to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer...

Enrolling
Colon Cancer
Medullary Thyroid Cancer
Drug: LOXO-292

Phase 1, Phase 2

Loxo Oncology
Loxo Oncology

Washington, District of Columbia, United States and 83 other locations

This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-010,...

Begins enrollment this month
Advanced Cancer
Endometrial Cancer
Drug: PHN-010

Phase 1

Pheon Therapeutics

Fairfax, Virginia, United States and 2 other locations

the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon...

Enrolling
Stage III Colon Cancer
Drug: mFOLFOX6 3-6 month
Device: Signatera test

Phase 2, Phase 3

NRG Oncology

Washington, District of Columbia, United States and 831 other locations

safety and clinical activity of nivolumab and relatlimab in patients with metastatic or locally advanced microsatellite stable (MSS) colorectal cancer...

Active, not recruiting
Colorectal Adenocarcinoma
Microsatellite Stable (MSS) Colorectal Adenocarcinomas
Drug: Relatlimab
Drug: Nivolumab

Phase 2

Johns Hopkins Medicine
Johns Hopkins Medicine

Baltimore, Maryland, United States

This study is to evaluate the safety and tolerability of RMC-9805 in adults with KRAS G12D-mutant solid tumors.

Enrolling
Non-small Cell Lung Cancer (NSCLC)
Colorectal Cancer (CRC)
Drug: RMC-9805

Phase 1

Revolution Medicines
Revolution Medicines

Fairfax, Virginia, United States and 6 other locations

A Phase 1 SAD/MAD dose escalation and expansion study to determine the safety and effectiveness of ²¹²Pb-DOTAM-GRPR1 in subjects with various GRPR-ex...

Enrolling
Breast Cancer
Colon Cancer
Drug: ²¹²Pb-DOTAM-GRPR1

Phase 1

Orano Med

Glen Burnie, Maryland, United States and 3 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems